ISSN 1662-4009 (online)

Previous issue | Volume 16 | ESPEYB16 | Next issue

Yearbook of Paediatric Endocrinology 2019

ey0016.13-1 | Diabetes | ESPEYB16

13.1. Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial

PC Rockers , RO Laing , PG Ashigbie , MA Onyango , CK Mukiira , VJ Wirtz

Lancet Glob Health 2019;7: e492–502. DOI: 10.1016/S2214-109X(18)30563-1• The authors evaluated the effect of a Novartis programme that provides metformin at a wholesale price of US$1 per month in Kenya.• This cluster-randomized controlled trial significantly increased the availability of metformin at health facilities, but not at patient househ...

ey0016.13-2 | Diabetes | ESPEYB16

13.2. Challenges associated with providing diabetes care in humanitarian settings

P Boulle , S Kehlenbrink , J Smith , D Beran , K Jobanputra

Lancet Diabetes Endocrinol 2019 Published Online March 13, 2019. DOI: 10.1016/S2213-8587(19)30083-X• Practical challenges associated with diabetes care in humanitarian contexts in low- and middle- income countries abound.• In this position paper, the authors articulate the important needs around diabetes care in the context of the 6 building blocks ...

ey0016.13-3 | Diabetes | ESPEYB16

13.3. Levels of type 1 diabetes care in children and adolescents for countries at varying resource levels

GD Ogle , JE von Oettingen , AC Middlehurst , R Hanas , TJ Orchard

Pediatr Diabetes. 2019;20:93–98. DOI: 10.1111/pedi.12801• The quality and availability of pediatric diabetes management varies from setting to setting depending on the available resources.• In this position paper, the authors propose a ‘levels of care’ concept with three tiers that stratifies the existing levels of care into minimal care, interm...

ey0016.13-4 | Diabetes | ESPEYB16

13.4. Why are we failing to address the issue of access to insulin? A national and global perspective

D Beran , B Hirsch , JS Yudkin

Diabetes Care 2018;41:1125–1131. DOI: 10.2337/dc18-er09a)• Many people currently in need of insulin are unable to access it.• Unaffordable price of insulin is a major barrier.• These authors analyse the causes of unsatisfactory access to insulin from a U.S. and global perspective.This article identifies the various ...

ey0016.13-5 | Diabetes | ESPEYB16

13.5. Blood glucose meters and test strips: Global market and challenges to access in low-resource settings

EL Klatman , AJ Jenkins , MY Ahmedani , GD Ogle

Lancet Diabetes Endocrinol 2019; 7: 150–60. DOI 10.1016/S2213-8587(18)30074-3• Access to blood glucose monitoring is often poor in resource-limited settings.• The authors analyse the reasons for suboptimal access, with a focus on cost, availability, system accuracy, competitive bidding, technological trends, and non-financial barriers. Urine gl...